Drug
Vrn101099
Vrn101099: highest development phase Phase 1, developed by Voronoi, Inc. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Voronoi, Inc
Trials
| Drug | Phase | Indication |
|---|---|---|
| VRN101099 NCT06806982 | Phase 1 | HER2-positive Solid Tumors |
Latest
No recent events.
Follow Vrn101099 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.